Latest Content

Quality of Life Maintained with Akeega Combo in Prostate Cancer

October 17th 2025, 9:28pm

By Bridget Hoyt

Article

For patients with HRRm prostate cancer receiving Akeega with prednisone, quality of life remained at baseline.

Open-Label Extension of Ponsegromab Shows Efficacy in Cancer-Associated Cachexia

October 17th 2025, 8:47pm

By Ryan Scott

Article

Ponsegromab improved body weight, suppressed GDF-15 and was well-tolerated over 64 weeks in cancer-associated cachexia, including patients switching from placebo.

Kisqali Plus Aromatase Inhibitor Shows Long-Term Benefit in Early Breast Cancer

October 17th 2025, 8:30pm

By Kyle Doherty

Article

Adding Kisqali to a nonsteroidal aromatase inhibitor continued to reduce recurrence risk and improve survival at five years in early breast cancer.

Imfinzi Plus Chemo Improves Survival in G/GEJ Adenocarcinoma

October 17th 2025, 8:26pm

By Andrea Eleazar, MHS

Article

Among patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma that is resectable, Imfinzi with FLOT improved survival.

Imfinzi Plus BCG Improves Disease-Free Survival in High-Risk NMIBC

October 17th 2025, 7:40pm

By Paige Britt

Article

Adding Imfinzi to Bacillus Calmette-Guérin therapy improved disease-free survival for patients with high-risk, non-muscle invasive bladder cancer.

Imfinzi Not Associated With Bladder Cancer Quality of Life Decline

October 17th 2025, 7:39pm

By Benjamin P. Saylor

Article

Among patients with muscle-invasive bladder cancer, perioperative Imfinzi to chemotherapy doesn’t have a detrimental effect on patient-reported outcomes.

Lenvima Combo Fails to Extend Survival in Esophageal Cancer

October 17th 2025, 7:00pm

By Caroline Seymour

Article

Lenvima and Keytruda with chemo did not help patients with metastatic esophageal squamous cell carcinoma live longer than Keytruda and chemotherapy alone.

Sevabertinib Effective in Pretreated and First-Line HER2-Mutant NSCLC

October 17th 2025, 6:20pm

By Tim Cortese

Article

Sevabertinib showed high response rates and durable disease control in patients with HER2-mutant NSCLC, with diarrhea as the main manageable side effect.

Supervised Physical Activity Does Not Improve Quality of Life in Metastatic Cancer

October 17th 2025, 5:27pm

By Alex Biese

Article

Home-based supervised physical activity has no major impact on fatigue and quality of life for patients with metastatic cancer receiving oral targeted therapy.

Durable Gleevec Benefit Doubles Survival in Advanced GIST

October 17th 2025, 5:07pm

By Spencer Feldman

Article

Gleevec remains effective in advanced gastrointestinal stromal tumors, with complete response or full tumor removal doubling median survival.

Tecentriq Plus BCG Does Not Improve Outcomes in Some With Bladder Cancer

October 17th 2025, 2:27pm

By Sabrina Serani

Article

The addition of Tecentriq to BCG therapy did not significantly improve outcomes for patients with non–muscle-invasive bladder versus BCG alone.

Areola Tattooing Helped Stephanie Wachtel Reclaim Confidence After Cancer

October 17th 2025, 1:00pm

By Stephanie Wachtel

Video

Stephanie Wachtel told CURE that areola tattooing after HER2-positive breast cancer helped her feel whole again and reconnect with her creativity.

Finding Love and Humanity in the Radiation Waiting Room

October 16th 2025, 9:00pm

By Monica Marcinak

Article

During her radiation treatments, Sister Monica Marcinak found grace, humor and deep compassion among fellow patients and caregivers facing cancer together.

Pancreatic Cancer Basics, From Diagnosis to Treatment

October 16th 2025, 8:00pm

By Alex Biese

Article

For patients with pancreatic cancer, this is a guide to the basics you need to know about this disease.

Gastrointestinal Stromal Tumor: Comprehensive Patient Guide

October 16th 2025, 7:00pm

By Spencer Feldman

Article

This patient guide explains gastrointestinal stromal tumors, covering diagnosis, treatment options, targeted therapies and practical care tips.